Skip to main content

Military Health System

Hepburn: DOD role in Operation Warp Speed was ‘transformative’

Image of Medical technician getting a syringe ready to give a vaccine. Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center Fort Sam Houston, Texas, November 16, 2020. BAMC is one of five Defense Health Agency military medical treatment facilities participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics. (Photo by Jason Edwards, Brooke Army Medical Center.)

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response | Coronavirus & the MHS Response | Coronavirus and the COVID-19 Vaccine

The director of the Department of Defense’s Operation Warp Speed told The Society of Federal Health Professionals that he is 'incredibly proud’ of the work his team has done with the Department of Health and Human Services in finding a vaccine for COVID-19. Dr. Matthew Hepburn’s praise for DOD came during a speech to the AMSUS virtual annual meeting Dec. 8.

The DOD’s role in Operations Warp Speed (OWS) was “transformative,” said Hepburn, OWS development lead, pointing to operational planning, logistics and supply chains, which “is in our DNA” at DOD. “It comes very naturally because that is what we do…and that has made all the difference,” he told the audience of more than 1,500 online attendees.

For example, he said DOD’s expertise in obtaining contracts quickly resulted in OWS getting “a really good deal in record time that was mutually beneficial” to the six vaccine manufacturers the joint operation decided to pursue for an approved vaccine for COVID-19. Those manufacturers are Pfizer, Moderna, AstraZeneca, Janssen, Novavax, and Sanofi.

“The Department of Defense’s unique contracting experience … and other transactions have allowed us to come from where we think are the right contacts to having long-term contracts,” Hepburn said.

Pfizer and Moderna have applied for emergency use authorization from the Food and Drug Administration. Pfizer’s application will be reviewed by an FDA advisory committee of vaccine experts Dec. 10, and Moderna’s application will be reviewed a week later. The FDA usually, but not always, accepts its advisory panels’ recommendations.

The FDA announced on Dec. 8 that its review of the Pfizer vaccine found it to be safe and efficacious, meeting the requirements for emergency use authorization. The vaccine showed a strong protective effect after the first of two doses, according to the FDA.

The OWS’ chief operating officer, Army Gen. Gustave Perna, “has been very clear that we will have trucks rolling within 24 hours of approval of the first vaccine,” Hepburn said.

Once the vaccine is first available to frontline health care workers and elderly care facilities, “we need you to tell our communities that this is just one layer of a multi-level strategy” to protect against COVID-19, he stated.

He urged the health care community “to convey a message that these vaccines are safe and efficacious, and that vaccination is important” as a counterpoint to widespread misinformation in the general public about vaccines and the need for vaccination against the disease.

Clinical trials for the candidate vaccines are ongoing and represent the diversity of the general population, Hepburn said, and were done “in anticipation of trying to increase confidence” among the public. For example, at least 25% of clinical trial participants are over the age of 65, a population not normally used for clinical trials but one at greater risk from COVID-19, he noted.

The number of doses needed for immunizations is “really a moving target, which is not necessarily a bad thing,” Hepburn said. “The consistency and cadence of manufacturing improves over time, and more doses are available than we thought would be available last week.”

OWS’ project team asks for “more doses on a daily basis,” he noted.

Armed services research efforts prior to the pandemic will allow for future innovation and speed of vaccine and therapeutics development, Hepburn said.

“If we hadn’t made those investments 10 years ago, there is no way we could have achieved the speed” of going from research and development, to candidates, to clinical trials, to approval and distribution, he said.

He noted that the DOD’s “clinical research enterprise led us to be involved in the enrollment right now in the AstraZeneca clinical trials.”

He called the department’s research enterprise “an incredibly powerful tool to confront 21st century threats,” and that “this is the new standard for rapid product development, and will apply not only to pandemics but also to develop product for combat health in half the time. Imagine how fast we could go in force protection” using the new paradigm, he said.

During a question and answer session, Hepburn emphasized that the AMSUS audience “needs to remind people at the DOD and in the community at large how well DOD can work” when confronted by new viral or other national security and health care threats.

“One of the most important lessons learned is the value of military leadership” in overcoming obstacles at a rapid clip, he said, noting the DOD “didn’t take over a public health initiative, but collaborated on a project that involved not only what we’re doing for the American people but also globally.”

You also may be interested in...

Provider Vaccine Conversation Guide

Publication
5/24/2021

This guide offers approaches and illustrative examples for Military Health System (MHS) providers to discuss the COVID-19 vaccine with servicemembers during routine visits. Initiating a COVID-19 vaccine conversation during servicemember visits will allow you to effectively address concerns, build trust, and boost vaccine confidence.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | COVID-19 Vax Facts

Unit Leader Vaccine Conversation Guide

Publication
5/24/2021

This guide offers approaches and illustrative examples for preparation, delivery, and navigation of small group discussions (recommended 1-5 people to facilitate greatest engagement) with servicemembers reluctant or indifferent to accepting the vaccine. The guide promotes an open dialogue regarding vaccine hesitancy and complacency by addressing concerns, building trust, and boosting vaccine confidence.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | COVID-19 Vax Facts

VAX Facts about Pregnancy

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

VAX Facts about Fertility

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

VAX Facts about Breastfeeding

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

VAX Facts about Having COVID-19

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

VAX Facts How Long does Protection Last?

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

VAX Facts Underlying Conditions

Publication
4/21/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts

COVID Vaccine Printable Pharmacy Insert

Publication
4/2/2021

An insert with links to learn more about vaccination options. Options include MTFs, state health departments, and local retail pharmacy. Graphics include medical personnel wearing masks on the bottom as well as the TRICARE logo.

Recommended Content:

Coronavirus and the COVID-19 Vaccine

Template: COVID-19 Vaccine Key Messages

Publication
3/17/2021

These are a list of important messages about the COVID-19 vaccine that you should share with your constituents.

Recommended Content:

Coronavirus and the COVID-19 Vaccine

Getting the COVID-19 Vaccine at Civilian Pharmacies

Publication
3/9/2021

YOU CAN GET THE COVID-19 VACCINE FROM ANY CIVILIAN PHARMACY AT NO CHARGE, EVEN NON-NETWORK PHARMACIES, BUT HERE ARE SOME THINGS TO KEEP IN MIND.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response

Access to COVID-19 Vaccine for Members of the Selected Reserve (SELRES)

Publication
3/2/2021

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response

Printable VAX Fact When can I get the COVID-19 Vaccine?

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Printable VAX Fact Can I Get COVID-19 From the Vaccine?

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Printable VAX Fact Where can I get the COVID-19 Vaccine?

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts
<< < 1 2 3 4 5 > >> 
Showing results 16 - 30 Page 2 of 5
Refine your search
Last Updated: August 23, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery